Divis Laboratories Ltd
Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients[1]
- Market Cap ₹ 99,999 Cr.
- Current Price ₹ 3,767
- High / Low ₹ 3,949 / 2,730
- Stock P/E 75.9
- Book Value ₹ 475
- Dividend Yield 0.79 %
- ROCE 19.3 %
- ROE 14.8 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 32.7%
Cons
- Stock is trading at 8.00 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1,845 | 2,129 | 2,514 | 3,084 | 3,720 | 4,024 | 3,816 | 4,880 | 5,311 | 6,799 | 8,880 | 7,625 | 7,196 | |
1,149 | 1,306 | 1,492 | 1,914 | 2,314 | 2,582 | 2,558 | 3,028 | 3,491 | 3,971 | 5,000 | 5,275 | 5,332 | |
Operating Profit | 696 | 823 | 1,022 | 1,170 | 1,406 | 1,441 | 1,258 | 1,851 | 1,820 | 2,828 | 3,880 | 2,350 | 1,863 |
OPM % | 38% | 39% | 41% | 38% | 38% | 36% | 33% | 38% | 34% | 42% | 44% | 31% | 26% |
66 | 49 | 81 | 36 | 92 | 73 | 106 | 155 | 187 | 57 | 109 | 348 | 347 | |
Interest | 5 | 3 | 3 | 3 | 4 | 3 | 2 | 5 | 7 | 2 | 2 | 2 | 1 |
Depreciation | 62 | 77 | 92 | 136 | 118 | 123 | 142 | 169 | 186 | 255 | 311 | 342 | 361 |
Profit before tax | 695 | 792 | 1,009 | 1,067 | 1,375 | 1,388 | 1,219 | 1,833 | 1,813 | 2,628 | 3,677 | 2,354 | 1,849 |
Tax % | 21% | 23% | 22% | 21% | 19% | 24% | 29% | 27% | 24% | 26% | 20% | 23% | |
546 | 611 | 792 | 847 | 1,111 | 1,053 | 870 | 1,333 | 1,373 | 1,955 | 2,949 | 1,808 | 1,317 | |
EPS in Rs | 20.56 | 23.03 | 29.82 | 31.90 | 41.84 | 39.68 | 32.76 | 50.20 | 51.71 | 73.63 | 111.07 | 68.11 | 49.61 |
Dividend Payout % | 32% | 33% | 34% | 31% | 24% | 25% | 31% | 32% | 31% | 27% | 27% | 44% |
Compounded Sales Growth | |
---|---|
10 Years: | 14% |
5 Years: | 15% |
3 Years: | 13% |
TTM: | -20% |
Compounded Profit Growth | |
---|---|
10 Years: | 11% |
5 Years: | 16% |
3 Years: | 11% |
TTM: | -56% |
Stock Price CAGR | |
---|---|
10 Years: | 21% |
5 Years: | 21% |
3 Years: | 1% |
1 Year: | 13% |
Return on Equity | |
---|---|
10 Years: | 22% |
5 Years: | 21% |
3 Years: | 22% |
Last Year: | 15% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 27 | 27 | 27 | 27 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 |
Reserves | 2,148 | 2,527 | 3,008 | 3,535 | 4,304 | 5,356 | 5,907 | 6,920 | 7,264 | 9,218 | 11,638 | 12,652 | 12,544 |
55 | 33 | 18 | 27 | 42 | 36 | 63 | 106 | 34 | 0 | 0 | 0 | 2 | |
573 | 610 | 731 | 886 | 566 | 765 | 785 | 961 | 1,164 | 1,452 | 1,617 | 1,646 | 1,575 | |
Total Liabilities | 2,803 | 3,196 | 3,784 | 4,475 | 4,965 | 6,210 | 6,808 | 8,040 | 8,514 | 10,724 | 13,308 | 14,352 | 14,174 |
738 | 908 | 1,222 | 1,309 | 1,439 | 1,559 | 1,996 | 2,087 | 2,776 | 3,699 | 4,321 | 4,719 | 4,651 | |
CWIP | 182 | 303 | 144 | 218 | 264 | 444 | 120 | 492 | 920 | 711 | 470 | 212 | 496 |
Investments | 480 | 411 | 505 | 736 | 813 | 1,639 | 1,897 | 1,953 | 979 | 7 | 79 | 84 | 87 |
1,403 | 1,573 | 1,913 | 2,212 | 2,450 | 2,568 | 2,795 | 3,508 | 3,839 | 6,307 | 8,438 | 9,337 | 8,940 | |
Total Assets | 2,803 | 3,196 | 3,784 | 4,475 | 4,965 | 6,210 | 6,808 | 8,040 | 8,514 | 10,724 | 13,308 | 14,352 | 14,174 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
334 | 483 | 558 | 822 | 1,036 | 1,149 | 765 | 964 | 1,208 | 1,947 | 1,910 | 2,448 | |
-204 | -254 | -305 | -521 | -411 | -1,137 | -476 | -684 | -81 | 75 | -2,195 | -2,707 | |
-131 | -231 | -248 | -303 | -630 | 3 | -314 | -246 | -1,091 | -34 | -532 | -797 | |
Net Cash Flow | -1 | -2 | 5 | -1 | -5 | 15 | -25 | 34 | 36 | 1,988 | -817 | -1,055 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 106 | 96 | 115 | 97 | 95 | 91 | 106 | 96 | 105 | 94 | 106 | 94 |
Inventory Days | 307 | 369 | 355 | 335 | 284 | 291 | 311 | 324 | 299 | 322 | 316 | 329 |
Days Payable | 74 | 72 | 59 | 67 | 56 | 103 | 98 | 94 | 99 | 118 | 92 | 88 |
Cash Conversion Cycle | 339 | 392 | 411 | 365 | 323 | 280 | 319 | 325 | 305 | 298 | 330 | 335 |
Working Capital Days | 149 | 156 | 165 | 149 | 169 | 156 | 191 | 181 | 186 | 155 | 178 | 190 |
ROCE % | 34% | 33% | 36% | 32% | 35% | 28% | 21% | 28% | 24% | 32% | 35% | 19% |
Documents
Announcements
- Disclosure Under Regulation 30 Of The SEBI(LODR) Regulations, 2015 16 Nov
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
11 Nov - Transcript of earnings conference call held on November 06, 2023.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 7 Nov
- Announcement under Regulation 30 (LODR)-Earnings Call Transcript 6 Nov
- Board Meeting Outcome for Outcome Of Board Meeting - Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended September 30, 2023 6 Nov
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from nse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
Concalls
-
Nov 2023TranscriptPPT
-
Nov 2023TranscriptPPT
-
Aug 2023TranscriptPPTREC
-
May 2023TranscriptPPTREC
-
Feb 2023TranscriptPPT
-
Nov 2022TranscriptPPT
-
Aug 2022TranscriptPPT
-
May 2022TranscriptPPT
-
Feb 2022TranscriptPPT
-
Nov 2021TranscriptPPT
-
May 2021TranscriptPPT
-
Jan 2021TranscriptPPT
-
Oct 2020TranscriptPPT
-
Aug 2020TranscriptPPT
-
May 2020TranscriptNotesPPTREC
-
Mar 2017TranscriptPPT
Business Overview:[1]
Company manufactures Generic Active pharmaceuticals ingredients, Custom synthesis of APIs & Intermediates along with Nutraceuticals for Global Pharmaceutical & Nutraceutical industry. These are segmented as:
a) Generic APIs:[2]
Company manufactures 30 Large Volume Generic APIs in 10’s to 100’s/1000’s of Tons each year and exports them to 100+ countries. Further, there are 10 APIs in various stages of R&D and pilot scale development
b) Custom Synthesis:[3]
Company under Custom Synthesis of APIs and Intermediates for global companies with a portfolio of products across diverse therapeutic areas. 12 out of top 20 Big Pharma Companies across US, EU and Japan have been associated with Divi’s for 10+ years
c) Nutraceutical:[4][5]
Company's Vishakhapatnam unit produces active ingredient and finished forms of Carotenoids. It is currently supplying carotenoids to all major food, dietary supplement and feed manufacturers globally. Company also offers customized ingredient solutions in liquids, beadlets and powder forms